An orally administered bacterial membrane protein nanodrug ameliorates doxorubicin cardiotoxicity through alleviating impaired intestinal barrier.
Li Z, Xing J, Ma X, Zhang W, Wang C, Wang Y, Qi X, Liu Y, Jian D, Cheng X, Zhu Y, Shi C, Guo Y, Zhao H, Jiang W, Tang H.
Li Z, et al. Among authors: jiang w.
Bioact Mater. 2024 Apr 25;37:517-532. doi: 10.1016/j.bioactmat.2024.03.027. eCollection 2024 Jul.
Bioact Mater. 2024.
PMID: 38698916
Free PMC article.